HK1094336A1 - Connective tissue growth factor antibodies - Google Patents

Connective tissue growth factor antibodies

Info

Publication number
HK1094336A1
HK1094336A1 HK07101399.8A HK07101399A HK1094336A1 HK 1094336 A1 HK1094336 A1 HK 1094336A1 HK 07101399 A HK07101399 A HK 07101399A HK 1094336 A1 HK1094336 A1 HK 1094336A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
growth factor
connective tissue
tissue growth
factor antibodies
Prior art date
Application number
HK07101399.8A
Other languages
English (en)
Inventor
Ai Y Lin
Thomas B Neff
Noelynn A Oliver
William R Usinger
Qingjian Wang
David A Yeowell
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of HK1094336A1 publication Critical patent/HK1094336A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
HK07101399.8A 2003-06-04 2007-02-07 Connective tissue growth factor antibodies HK1094336A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47559803P 2003-06-04 2003-06-04
US10/858,186 US7405274B2 (en) 2003-06-04 2004-06-01 Connective tissue growth factor antibodies
PCT/US2004/017080 WO2004108764A2 (en) 2003-06-04 2004-06-02 Connective tissue growth factor antibodies

Publications (1)

Publication Number Publication Date
HK1094336A1 true HK1094336A1 (en) 2007-05-04

Family

ID=33493433

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07101399.8A HK1094336A1 (en) 2003-06-04 2007-02-07 Connective tissue growth factor antibodies

Country Status (17)

Country Link
US (9) US7405274B2 (es)
EP (3) EP1631591B1 (es)
JP (2) JP5624707B2 (es)
KR (1) KR101244113B1 (es)
CN (2) CN1829740B (es)
AT (1) ATE538136T1 (es)
AU (1) AU2004245514B2 (es)
BR (1) BRPI0410963B8 (es)
CA (1) CA2526509C (es)
DK (1) DK1631591T3 (es)
ES (1) ES2379662T3 (es)
HK (1) HK1094336A1 (es)
IL (1) IL172328A (es)
NO (1) NO336451B1 (es)
NZ (1) NZ543522A (es)
RU (1) RU2330861C2 (es)
WO (1) WO2004108764A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1140969T3 (da) * 1998-12-14 2007-09-17 Univ Miami Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
WO2005077413A1 (en) 2004-02-11 2005-08-25 Fibrogen, Inc. Ctgf as target for the therapy of diabetic nephropathy
WO2005110479A2 (en) * 2004-04-28 2005-11-24 Fibrogen, Inc. Treatments for pancreatic cancer
EP1891109A1 (en) * 2005-05-05 2008-02-27 Fibrogen, Inc. Cardiovascular disease therapies
JP2009510056A (ja) * 2005-09-29 2009-03-12 ファイブローゲン、インコーポレーテッド 血圧を低下させる方法
JP2008295328A (ja) * 2007-05-30 2008-12-11 Fujifilm Corp 卵巣癌の検出方法、及び抑制方法
EP2949752B1 (en) 2008-09-22 2017-12-20 RXi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
WO2010042202A1 (en) * 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
WO2010042201A1 (en) * 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of focal segmental glomerulosclerosis
EP2221387A1 (en) * 2009-02-19 2010-08-25 Université de la Méditerranée Fibrosis susceptibility gene and uses thereof
US20110110953A1 (en) * 2009-06-29 2011-05-12 Dennis Keith Bishop Compound and method for treatment of chronic transplant rejection
WO2011002525A1 (en) 2009-07-02 2011-01-06 Fibrogen, Inc. Methods for treatment of muscular dystrophy
WO2011056234A1 (en) * 2009-11-06 2011-05-12 Fibrogen, Inc. Treatment for radiation-induced disorders
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
CN110042099A (zh) 2010-03-24 2019-07-23 菲奥医药公司 皮肤与纤维化症候中的rna干扰
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
WO2012100262A1 (en) 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
US20140065162A1 (en) * 2011-11-08 2014-03-06 Fibrogen, Inc. Compositions and Methods for Treating Brain Tumors
AR089425A1 (es) 2011-12-22 2014-08-20 Astellas Pharma Inc Anticuerpo ctgf (factor de crecimiento de tejido conectivo) antihumano
WO2013108869A1 (ja) * 2012-01-20 2013-07-25 国立大学法人岡山大学 がんの治療又は予防剤
WO2013148159A1 (en) * 2012-03-30 2013-10-03 Fibrogen Inc Therapeutic methods for peritoneal carcinomatosis
US9480449B2 (en) 2012-05-03 2016-11-01 Fibrogen, Inc. Methods for treating idiopathic pulmonary fibrosis
EP3049088B1 (en) * 2013-09-26 2021-02-17 Galderma S.A. Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring
US9631013B2 (en) 2014-01-28 2017-04-25 Fibrogen, Inc. Therapeutic method for pancreatic cancer
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
CN104740628B (zh) * 2015-02-12 2017-09-26 西安交通大学医学院第一附属医院 用于治疗肝纤维化的结缔组织生长因子嵌合疫苗及其应用
WO2016205226A1 (en) * 2015-06-15 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating affective disorders
US11299537B2 (en) 2015-12-10 2022-04-12 Fibrogen, Inc. Methods for treatment of motor neuron diseases
RU2764919C2 (ru) 2016-06-13 2022-01-24 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Оптимизированные гены и экспрессионные кассеты cln1, и их применение
WO2019221576A1 (ko) * 2018-05-17 2019-11-21 광주과학기술원 Ccn5를 유효성분으로 포함하는 망막질환 예방 또는 치료용 약학 조성물
WO2020009248A1 (ja) * 2018-07-04 2020-01-09 京都府公立大学法人 眼組織の線維化抑制用組成物
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN109824777A (zh) * 2019-03-15 2019-05-31 辽宁何氏医学院 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
WO2020244540A1 (zh) * 2019-06-04 2020-12-10 江苏恒瑞医药股份有限公司 抗结缔组织生长因子抗体及其应用
EP3821946A1 (en) * 2019-11-12 2021-05-19 Université de Strasbourg Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases
CN112266417B (zh) * 2020-10-27 2022-02-11 温州医科大学 一种以结缔组织生长因子为靶点的全人源拮抗抗体及其应用
CA3200705A1 (en) * 2020-12-03 2022-06-09 Xiazhen MA Pharmaceutical composition comprising anti-connective tissue growth factor antibody
CN115645525B (zh) * 2022-12-14 2023-04-14 北京大学第三医院（北京大学第三临床医学院） Ctgf中和抗体在制备防治绝经后骨关节炎的药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US587670A (en) 1897-08-03 Combined high-pressure throttle and reducing valve
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5837258A (en) * 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1996008140A1 (en) 1994-09-15 1996-03-21 Fred Nordberg Electric fence device
US5876730A (en) 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
JPH11180895A (ja) 1997-09-12 1999-07-06 Masaharu Takigawa 血管新生阻害剤
EP1043335A4 (en) 1997-12-25 2005-08-31 Japan Tobacco Inc MONOCLONAL ANTIBODY AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND ITS MEDICAL APPLICATIONS
JP4537507B2 (ja) * 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
AU6138799A (en) 1998-09-08 2000-03-27 Fibrogen, Inc. Method for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
US6348329B1 (en) 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
DK1140969T3 (da) 1998-12-14 2007-09-17 Univ Miami Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20030113816A1 (en) * 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor
JP2005519881A (ja) 2001-12-11 2005-07-07 ファイブローゲン、インコーポレーテッド 眼プロセスの抑制方法
US20190127456A1 (en) * 2017-10-31 2019-05-02 Fibrogen, Inc. Methods of treating idiopathic pulmonary fibrosis

Also Published As

Publication number Publication date
EP1631591A2 (en) 2006-03-08
NZ543522A (en) 2008-06-30
ES2379662T3 (es) 2012-04-30
US20160024198A1 (en) 2016-01-28
CN103539858A (zh) 2014-01-29
IL172328A (en) 2012-01-31
NO20060027L (no) 2006-01-03
US20160257740A1 (en) 2016-09-08
JP2012143239A (ja) 2012-08-02
JP5753506B2 (ja) 2015-07-22
KR101244113B1 (ko) 2013-03-18
US20140073047A1 (en) 2014-03-13
AU2004245514B2 (en) 2009-10-01
EP2322549A1 (en) 2011-05-18
BRPI0410963A (pt) 2006-07-04
JP5624707B2 (ja) 2014-11-12
BRPI0410963B1 (pt) 2019-10-08
US7871617B2 (en) 2011-01-18
JP2007525194A (ja) 2007-09-06
WO2004108764A3 (en) 2005-03-03
CN1829740A (zh) 2006-09-06
US9034643B2 (en) 2015-05-19
US20040248206A1 (en) 2004-12-09
CA2526509C (en) 2013-08-06
EP2338914A1 (en) 2011-06-29
NO336451B1 (no) 2015-08-24
DK1631591T3 (da) 2012-04-10
US7405274B2 (en) 2008-07-29
US20190023778A1 (en) 2019-01-24
ATE538136T1 (de) 2012-01-15
AU2004245514A1 (en) 2004-12-16
RU2005141492A (ru) 2007-07-20
EP1631591B1 (en) 2011-12-21
US20240076364A1 (en) 2024-03-07
RU2330861C2 (ru) 2008-08-10
US20110091468A1 (en) 2011-04-21
KR20060030032A (ko) 2006-04-07
CN1829740B (zh) 2013-05-29
US20210230259A1 (en) 2021-07-29
BRPI0410963B8 (pt) 2021-05-25
US20090017043A1 (en) 2009-01-15
WO2004108764A2 (en) 2004-12-16
CA2526509A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
HK1094336A1 (en) Connective tissue growth factor antibodies
WO2003083041A3 (en) Cripto-specific antibodies
SI1615952T1 (sl) Metoda zdravljenja vnetnih bolezni z uporabo specifičnih veznih sredstev humanega angiopoetin
WO2006014729A3 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
HK1076113A1 (en) Specific binding agents of human angiopoietin-2
WO2006026617A3 (en) Compositions and methods of promoting hair growth
WO2005113590A3 (en) Bmp10 propeptides and related methods
MXPA05012723A (es) Tratamiento con anticuerpos anti-vgf.
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
MX2007013834A (es) Terapias de enfermedades vasculares.
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2004081229A3 (en) Use of bv8 and/or eg-vegf to promote hematopoiesis
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
WO2005058280A3 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
WO2003092669A3 (en) Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
WO2003032899A3 (en) Methods and materials for targeting and affecting selected cells
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
WO2003037257A3 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
WO2005077018A3 (en) Methods of treating skin disorders
WO2002062204A3 (en) Methods for diagnosing and treating heart disease
WO2007062000A3 (en) Fibroblast growth factor-5 and uses thereof
WO2005020923A3 (en) Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis
WO2004049917A3 (en) Methods of therapy and diagnosis using targeting of cells that express ly-9
ATE490981T1 (de) Criptospezifische antikörper
WO2004021991A3 (en) Asialo-interferons and the treatment of liver cancer

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240601